ROSA MARÍA
AYALA DÍAZ
Profesora titular de universidad
Instituto de Salud Carlos III
Madrid, EspañaInstituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (7)
2022
-
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols
British Journal of Haematology, Vol. 196, Núm. 3, pp. 670-675
-
The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies
Cancers, Vol. 14, Núm. 5
2021
-
Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients
International Journal of Laboratory Hematology
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
-
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial
Cancers, Vol. 13, Núm. 10
2020
-
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity
British Journal of Haematology, Vol. 189, Núm. 4, pp. 672-683
2019
-
MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
Scientific reports, Vol. 9, Núm. 1, pp. 18630